Azenta (AZTA) stock fell over 30% in 2025 due to ongoing sales weakness and structural challenges. The company’s struggles with drug development, clinical research, and cell therapies have led to reduced investor confidence and selling pressure, with analysts expressing caution about future outperformance.

Revenue for Azenta has declined, with the company’s top line contracting from $170 million to $156.67 million in the most recent quarter. Challenges in sustaining annual revenue above $500 million persist, with uncertainty in the macro environment affecting capital spending from customers, including biotech and gene therapy firms.

Azenta’s EPS estimates for fiscal 2026 and FY27 have decreased by over 10% in the last 60 days. Despite the stock trading at $34 a share, it still holds a high forward P/E multiple of 46X, indicating a premium to the S&P 500. Without sustained revenue growth or operational improvements, Azenta may continue to face pressure.

Zacks Investment Research is naming the top 10 stocks for 2026, with historical performance suggesting significant potential. The Zacks Top 10 Stocks have gained over 2,530% since 2012, surpassing the S&P 500’s growth. The new top picks for 2026 will be released on January 5, providing an opportunity for investors to get in early on high-performing stocks.

Read more at Nasdaq: Bear of the Day: Azenta (AZTA)